Adagene (ADAG) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

$1.6M

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$16.4M

Net income growth (year over year)

−21.53%

Net margin

—

Return on equity

−28.50%

EPS (trailing twelve months)

−$0.38

Book value per share

$1.58

P/E (trailing twelve months)

—

Price to book

1.56

Debt to assets

20.64%

Payout ratio

—

Dividend yield

—

Company profile

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

• How do I buy stock in Adagene (ADAG)?

  ADAG trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.